Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Apr 3, 2022 in Rheumatoid Arthritis | 0 comments

In a nutshell

This study investigated the effect of filgotinib (Jyseleca) on patient-reported outcomes (PROs) and health-related quality of life (HRQoL) in patients that had active rheumatoid arthritis (RA). The study showed that filgotinib improved PROs in these patients and can be a treatment option for patients with insufficient responses to methotrexate (Otrexup; MTX), biological disease-modifying anti-rheumatic drugs (bDMARDs), and those that are MTX-naive (have never received MTX).

Some background

RA is an inflammatory disease that causes pain and swollen joints. Medications to manage RA include anti-inflammatory drugs such as corticosteroids, MTX, or bDMARDs. However, there are still patients that do not respond adequately to these medications. New treatments are needed for these patients. 

Filgotinib is a once-daily administered oral medication used to treat RA, known as a Janus-kinase 1 (JAK1) preferential inhibitor. It causes a reduction in inflammation. The results from three Phase 3 studies that included patients with inadequate responses to MTX or bDMARDs and those not treated with MTX (MTX-naive) for early RA, indicated improved symptoms and function. However, there is a need to further analyze PROs measured during these studies to assess the effect of filgotinib on HRQoL in these patients.

Methods & findings

This study analyzed the PROs of three Phase 3 trials. One trial involved 1249 MTX-naive patients that received 200 mg of filgotinib with MTX (FIL200+MTX) or 100 mg of filgotinib with MTX (FIL100+MTX). The second trial included 1755 patients with an inadequate response (IR) to MTX (MTX-IR). Patients had received 200 mg of filgotinib with MTX (FIL200+MTX), 100 mg of filgotinib with MTX (FIL100+MTX), 40 mg of adalimumab with MTX (ADA+MTX), or a placebo (PBO) with MTX. The placebo group was assigned to FIL100+MTX and FIL200+MTX from week 24 to week 52. The final trial included 448 patients with an IR to bDMARDs (bDMARD-IR). Patients received FIL100, FIL200, or PBO with background stable conventional synthetic DMARDs (csDMARDs) for up to 24 weeks. Patients were assessed using standard PRO measurements.

Patients on once-daily 100 mg or 200 mg doses of filgotinib with MTX or csDMARDs who were MTX-naive or had an IR to MTX or bDMARDs developed improved functional status, physical health-related quality of life (HRQL), reduced fatigue, better work productivity, and improved disease activity. Filgotinib and MTX resulted in similar or better improvements compared to ADA+MTX in patients with an IR to MTX for up to 52 weeks.

The bottom line

The study showed that once-daily filgotinib, given at 200 mg or 100 mg in combination with MTX or csDMARDs, resulted in improved functional status, HRQL, fatigue, work impairment, and disease-activity measures in patients with active RA.

The fine print

The study with bDMARD-IR was short and included a small number of patients. 

Published By :

Arthritis Research & Therapy

Date :

Jan 03, 2022

Original Title :

The impact of filgotinib on patient-reported outcomes and health-related quality of life for patients with active rheumatoid arthritis: a post hoc analysis of Phase 3 studies.

click here to get personalized updates